Navigation Links
Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
Date:9/24/2008

SAN MATEO, Calif., Sept. 24 /PRNewswire/ -- Anthera Pharmaceuticals announced today they have reached agreement with the U.S. Food and Drug Administration (FDA) on a Phase 3 protocol for varespladib (A-002) in acute coronary syndrome (ACS) under the FDA's Special Protocol Assessment procedure. At the same time, the company received Scientific Advice from the European Medicines Agency (EMEA) on Anthera's European development strategy for varespladib. Guidance from both regulatory agencies regarding varespladib will be incorporated into Anthera's global registration program slated to start next year.

Anthera's Special Protocol Assessment supports a single, pivotal, Phase 3 trial evaluating varespladib, in combination with Lipitor(R) (atorvastatin) as first-line treatment within 96 hours of an ACS event. In the European Union, Anthera received Scientific Advice that supports a similar clinical development program and include the potential to also utilize varespladib as an adjunctive treatment in patients with stable coronary disease and elevated levels of LDL-C and total cholesterol.

"We are pleased that both agencies recognized the potential of varespladib's multiple therapeutic effects in patients with cardiovascular disease," said Paul Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "The anti-inflammatory effect and safety profile seen in the varespladib trials to date are very exciting and highlight the opportunity to help patients with recent coronary events."

"The regulatory clarity in the United States and Europe reinforces our confidence that we can efficiently deliver a novel therapeutic for patients with ACS," said Dr. Ursula Fritsch, Vice-President Global Regulatory and Compliance. "With this regulatory feedback, we have a clearly defined and reasonable development path to deliver a first in class therapeutic for ACS patients and individuals with hypercholesterolemia."

"The recent publication of clinical data at the European Society of Cardiologists by GlaxoSmithKline on the effect of their selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor, darapladib, on a secondary biological outcome while having no effect on inflammation or LDL-C, provides encouraging validation of the anatomical importance of reducing PLA2 activity in a cardiovascular population," said Dr. Robert S. Rosenson, Director of Lipoprotein Disorders and Clinical Atherosclerosis Research at the University of Michigan. "The on-going FRANCIS trial with varespladib, which is designed to evaluate and repeat the results of previous clinical data from PLASMA and PLASMA2 in an ACS population, should provide additional data on an already validated predictor of cardiovascular risk (LDL-C) coupled with reductions in PLA2."

In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of the target enzyme sPLA2, clinically meaningful and statistically significant reductions in "bad" LDL cholesterol, and a reduction in C-reactive protein, a known marker of inflammation.

Presently, the company is conducting the five hundred patient FRANCIS trial (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) to assess the impact of oral varespladib on known biological markers of cardiovascular risk in ACS patients with elevated LDL and CRP. FRANCIS will also provide insight into the prevention of secondary Major Adverse Cardiovascular Events (MACE) over the duration of the six-month trial.

About Acute Coronary Syndrome

Acute coronary syndrome is a heart condition characterized by chest pain occurring at rest or upon minimal exertion. This condition is also referred to as unstable angina. If the chest pain is associated with heart muscle damage and heart tracing abnormalities, it is typically classified as a heart attack or myocardial infarction.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.‚ Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes‚ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel‚ upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com.

INVESTOR AND MEDIA CONTACT: Anne Bowdidge, (650) 218-6900, pr@anthera.com


'/>"/>
SOURCE Anthera Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
7. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
8. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
9. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
10. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
11. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017 MouthWatch LLC announced today that its flagship ... the best intraoral camera on DentalCompare,s list of Top ... The #1 product was the CollaPlug Absorbable Collagen Wound ... was "…incredibly popular because it is by far the most ... sticker price, it doesn,t sacrifice quality imaging." ...
(Date:1/23/2017)... TORONTO , Jan. 23, 2017 ... both 510(k) clearance from the U.S. Food and ... from Health Canada enabling the North American commercial ... (MIGS™) system for spine surgery, the 7D Surgical ... employs cutting-edge 3D optical technologies and machine vision ...
(Date:1/23/2017)... 2017 Research and Markets has announced the addition ... Product - Forecast to 2025" report to their offering. ... Report Highlights: ... to identify the investment opportunities Market forecasts till 2025, ... market trends across the business segments, Regions and Countries ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... for life science companies, has achieved ISO 17100:2015 certification following a comprehensive ... 17100 is the globally recognized standard that establishes guidance for critical processes ...
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is proud to ... Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment ... to address the limitations of fatigue monitoring technologies within the mining industry. Today ...
(Date:1/23/2017)... ... ... boards have been around since at least the 1950s and are a great way to ... balance board to use a patent-pending design featuring high-pressure inflation technology and drop-stitch materials. ... skill-level adjustable for all ages and abilities. The board can be rolled up when ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and ... the benefits of making new water infrastructure a number one priority. “As we usher ... expect water infrastructure to become a top priority of our new political change agents.” ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Living (IHCA/INCAL), will serve as a healthcare industry expert at the 2017 Sector ... discussion, moderated by Inside Indiana Business host Gerry Dick, will feature an employer ...
Breaking Medicine News(10 mins):